改良诊断活检适应免疫评分对新辅助治疗后直肠癌患者的预后和预测价值:STELLAR试验的转化研究
研究纳入181例局部晚期直肠癌患者,来自比较短期放疗为基础的全新辅助治疗(TNT)与长期放化疗(CRT)的前瞻性研究单中心,基线活检评估CD8+和CD3+ T细胞密度构建改良诊断活检适应免疫评分(mISb)。mISb高组3年无病生存率85.5%优于低组57.2%(P=0.01),mISb为手术患者无病生存的独立预后因素(P=0.01),TNT亚组高mISb者无进展生存更长(P=0.049),CRT人群无显著差异。
要点
- mISb高组3年无病生存率85.5%,低组57.2%,中组68.6%(P=0.01)。
- mISb是手术患者无病生存的独立预后因素(P=0.01)。
- TNT亚组高mISb者无进展生存更长(P=0.049),CRT人群无显著差异。
核心结论
- mISb在接受术前治疗的局部晚期直肠癌患者中显示出显著预后价值,尤其在TNT亚组。
- 这些发现可能有助于为患者制定新辅助治疗的强度。
研究设计与样本
- 研究纳入181例局部晚期直肠癌患者,来自比较基于短期放疗的TNT与长期CRT的前瞻性研究的单中心。
- 基线肿瘤活检染色CD8+和CD3+ T细胞密度,使用CD8+ T细胞密度和CD8/CD3比值的平均百分位数构建mISb。
- 患者分为低(0%-25%)、中(>25%-70%)、高(>70%-100%)三组,采用生存分析和Cox回归模型比较mISb与诊断活检免疫评分的预后价值。
主要发现
- 151例(83.4%)患者接受手术,30例(16.6%)采取观察等待策略。
- CD8+与CD3+ T细胞密度强相关(R=0.86;P<.001),CD8+与CD8/CD3比值弱相关(R=0.45)。
- 整个队列3年无病生存率为69.9%,低、中、高mISb组分别为57.2%、68.6%、85.5%(P=.01),诊断活检免疫评分未能区分生存结局。
- 多变量分析显示mISb是手术患者无病生存的独立预后因素(P=.01)。
- TNT队列中高mISb评分患者无进展生存长于其他亚组(P=.049),CRT人群无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to assess the prognostic significance of the modified diagnostic biopsy-adapted immunoscore (mISb) in determining the outcomes for patients with locally advanced rectal cancer (LARC) in a neoadjuvant setting. METHODS AND MATERIALS: We included 181 patients with LARC from a single subcenter of a prospective study comparing total neoadjuvant therapy (TNT) based on short-course radiation therapy with long-term chemoradiation therapy (CRT). Tumor biopsies at baseline were stained for CD8+ and CD3+ T-cell densities. The mISb was developed using mean percentile of CD8+ T-cell density and CD8/CD3 ratio. Patients were classified into low (0%-25%), intermediate (>25%-70%), and high (>70%-100%) in both groups. The relativity among different lymphocytes and their correlation with survival were illustrated. Survival analyses and Cox regression models were used to compare the prognostic values of mISb and diagnostic biopsy immunoscore for survival outcomes and to assess the role of mISb in TNT and CRT subgroups, respectively. RESULTS: In this study, 151 (83.4%) patients received surgery, and 30 (16.6%) followed a watch and wait strategy. A strong correlation was found between CD8+ and CD3+ T-cell densities (R = 0.86; P < .001), whereas a weak correlation was witnessed between CD8+ and CD8/CD3 ratio (R = 0.45). The 3-year disease-free survival for the entire cohort was 69.9%, with 57.2%, 68.6%, and 85.5% for the low, intermediate, and high mISb groups, respectively (P = .01), whereas diagnostic biopsy immunoscore failed to distinguish survival outcomes. Multivariate analysis revealed mISb to be an independent prognostic factor for disease-free survival in surgically treated patients (P = .01). Specifically, patients with high mISb score showed longer progression-free survival than other subgroups in the TNT cohort (P = .049), but no significant difference was found in the CRT population. CONCLUSIONS: In this study, mISb demonstrated significant prognostic value in patients with LARC receiving preoperative therapies, especially in the TNT subgroup. These findings may help tailor the intensity of neoadjuvant therapy for patients.
引用
- Zeng Q, Yang YX, Tang Y, et al. Prognostic and Predictive Value of a Modified Diagnostic Biopsy-Adapted Immunoscore in Patients with Rectal Cancer After Neoadjuvant Treatment: A Translational Study From the STELLAR Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39426571. doi:10.1016/j.ijrobp.2024.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。